{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:35:10Z","timestamp":1794335710358,"version":"4.9.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.vaccine.2009.02.016","type":"journal-article","created":{"date-parts":[[2009,2,14]],"date-time":"2009-02-14T15:23:56Z","timestamp":1234625036000},"page":"2220-2229","source":"Crossref","is-referenced-by-count":29,"title":["CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague"],"prefix":"10.1016","volume":"27","author":[{"given":"Kei","family":"Amemiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taralyn E.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy L.","family":"Fast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Worsham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford S.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur M.","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Adamovicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.02.016_bib1","series-title":"Biological weapons defense: infectious diseases and counterbioterrorism","first-page":"121","article-title":"Plague vaccines","author":"Adamovicz","year":"2005"},{"issue":"6","key":"10.1016\/j.vaccine.2009.02.016_bib2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1517\/14712598.4.6.965","article-title":"Yersinia pestis (plague) vaccines","volume":"4","author":"Titball","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2009.02.016_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4049\/jimmunol.68.2.131","article-title":"Studies on immunization against plague. 1. The isolation and characterization of the soluble antigen of Pasteurella pestis","volume":"68","author":"Baker","year":"1952","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2009.02.016_bib4","first-page":"481","article-title":"The basis of virulence in Pasteurella pestis: an antigen determining virulence","volume":"35","author":"Burrows","year":"1956","journal-title":"Brit J Exper Pathol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4049\/jimmunol.91.2.179","article-title":"Biosynthesis and purification of the V and W antigen in Pasteurella pestis","volume":"91","author":"Lawton","year":"1963","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4049\/jimmunol.84.5.475","article-title":"Studies on the antigens of Pasteurella pestis and Pasteurella psuedotuberculosis","volume":"84","author":"Lawton","year":"1960","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1574-695X.1995.tb00196.x","article-title":"A new improved sub-unit vaccine for plague: the basis of protection","volume":"12","author":"Williamson","year":"1995","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib8","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0264-410X(98)80110-2","article-title":"Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine","volume":"16","author":"Heath","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib9","series-title":"Vaccines 97","first-page":"197","article-title":"A recombinant capsular F1-V antigen fusion protein vaccine protects against experimental bubonic and pneumonic plague","author":"Heath","year":"1997"},{"key":"10.1016\/j.vaccine.2009.02.016_bib10","series-title":"Vaccine adjuvants and delivery systems","first-page":"157","article-title":"Immunostimulatory CpG oligodeoxynucleotides as vaccine adjuvants","author":"Klinman","year":"2007"},{"key":"10.1016\/j.vaccine.2009.02.016_bib11","first-page":"59","article-title":"Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA","volume":"311","author":"McCluskie","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signaling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/mpat.1997.0154","article-title":"Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain CO92","volume":"23","author":"Welkos","year":"1997","journal-title":"Microb Pathogen"},{"key":"10.1016\/j.vaccine.2009.02.016_bib14","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1086\/520547","article-title":"Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague","volume":"196","author":"Heine","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.02.016_bib15","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1021\/bp050098r","article-title":"Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague","volume":"21","author":"Powell","year":"2005","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.vaccine.2009.02.016_bib16","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/01.aids.0000183514.37513.d2","article-title":"CpG 7909 adjuvant improves Hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults","volume":"19","author":"Cooper","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2009.02.016_bib17","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.164.3.1617","article-title":"Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo","volume":"164","author":"Hartmann","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1586\/14760584.7.3.287","article-title":"Vaccine adjuvant formulation: a relatively neglected field that is crucial to vaccine success","volume":"7","author":"Davies","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2009.02.016_bib19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2005.09.021","article-title":"Interleukin-12 induces a Th1-like response to Burkholderia mallei and limited protection in BALB\/c mice","volume":"24","author":"Amemiya","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib20","series-title":"Probit analysis","author":"Finney","year":"1971"},{"key":"10.1016\/j.vaccine.2009.02.016_bib21","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1128\/IAI.71.9.5178-5187.2003","article-title":"Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice","volume":"71","author":"Su","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.02.016_bib22","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1016\/j.vaccine.2007.05.007","article-title":"Enhanced antibody production in mice to the malaria antigen AMA1 by CpG 7909 requires physical association of CpG and antigen","volume":"25","author":"Mullen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib23","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00002371-200411000-00006","article-title":"Induction of systemic Th1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CpG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist","volume":"27","author":"Krieg","year":"2004","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2009.02.016_bib24","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood.V98.4.1217","article-title":"Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in na\u00efve and bone marrow transplant recipients","volume":"98","author":"Blazar","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2009.02.016_bib25","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1128\/IAI.68.3.1450-1456.2000","article-title":"CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide Immunoglobulin G2a (IgG2a) and IgG3 antibodies","volume":"68","author":"Chu","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.02.016_bib26","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1128\/IAI.74.3.1944-1948.2006","article-title":"A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei","volume":"74","author":"Waag","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.02.016_bib27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.186.10.1623","article-title":"CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity","volume":"186","author":"Chu","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.02.016_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.iy.08.040190.001511","article-title":"Lymphokine control of in vivo immunoglobulin isotype selection","volume":"8","author":"Finkelman","year":"1990","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib29","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1128\/IAI.69.8.4816-4822.2001","article-title":"Protection of BALB\/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant","volume":"69","author":"Al-Mariri","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.02.016_bib30","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1016\/j.vaccine.2007.05.009","article-title":"The role of CpG ODN in enhancement of immune response and protection in BALB\/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome","volume":"25","author":"Jaafari","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib31","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1016\/j.vaccine.2008.03.031","article-title":"Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen","volume":"26","author":"Mutwiri","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib32","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.vaccine.2008.03.005","article-title":"Addition of CpG ODN to recombinant Psuedomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders","volume":"26","author":"Qian","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0264-410X(00)00172-9","article-title":"CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi","volume":"19","author":"Corral","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib34","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4049\/jimmunol.160.2.870","article-title":"CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant Hepatitis B surface antigen","volume":"160","author":"Davis","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib35","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.vaccine.2006.09.052","article-title":"Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague","volume":"25","author":"Williamson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib36","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.vaccine.2004.10.025","article-title":"Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens","volume":"23","author":"Glynn","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00126839-200809030-00001","article-title":"A review of the role of CpG oligodeoxynucleotides as Toll-like receptor 9 agonists in prophylatic and therapeutic vaccine development in infectious diseases","volume":"9","author":"Gupta","year":"2008","journal-title":"Drugs R D"},{"key":"10.1016\/j.vaccine.2009.02.016_bib38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/108729003768247628","article-title":"Safety of CpG oligodeoxynucleotides in veterinary species","volume":"13","author":"Ioannou","year":"2003","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.vaccine.2009.02.016_bib39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1517\/14712598.4.6.937","article-title":"Use of CpG oligodeoxynucleotides ad immunoprotective agents","volume":"4","author":"Klinman","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2009.02.016_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Toll-like receptor 9 activation","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2009.02.016_bib41","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1128\/IAI.67.11.5658-5663.1999","article-title":"Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection","volume":"67","author":"Klinman","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.02.016_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1196\/annals.1348.030","article-title":"CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine","volume":"1082","author":"Klinman","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2009.02.016_bib43","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0264-410X(99)00526-5","article-title":"CpG DNA induces stronger immune responses with less toxicity than other adjuvants","volume":"18","author":"Weeratna","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.mlg.0000194222.93067.f7","article-title":"Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant","volume":"116","author":"Kodama","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.vaccine.2009.02.016_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1128\/CVI.00420-07","article-title":"Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: Safety data and interferon-inducible protein-10 kinetics for humans and macaques","volume":"15","author":"Stewart","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib46","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.4049\/jimmunol.168.4.1659","article-title":"CpG oligodeoxynucleotides as vaccine adjuvants in primates","volume":"168","author":"Verthelyi","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1521-6616(03)00202-X","article-title":"Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates","volume":"109","author":"Varthelyi","year":"2003","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib48","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CpG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib49","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1016\/j.vaccine.2004.01.058","article-title":"Safety and immunogenicity of CpG 7909 injection as an adjuvant to Fluarix influenza vaccine","volume":"22","author":"Cooper","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib50","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0264-410X(03)00045-8","article-title":"A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant","volume":"21","author":"Halperin","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib51","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/hep.21773","article-title":"Phase 1B, randomized, double-blind, dose-escalation trial of CpG 10101 in patients with chronic Hepatitis C virus","volume":"46","author":"McHutchison","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2009.02.016_bib52","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2009.02.016_bib53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.0105-2896.2004.00148.x","article-title":"Use of CpG oligodeoxynucleotides as immune adjuvants","volume":"199","author":"Klinman","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2009.02.016_bib54","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib55","doi-asserted-by":"crossref","first-page":"10649","DOI":"10.1073\/pnas.0504728102","article-title":"A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence","volume":"102","author":"Sing","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2009.02.016_bib56","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1084\/jem.20020908","article-title":"Yersinia V-antigen exploits Toll-like receptor 2 and CD14 for Interleukin 10-mediated immunosuppression","volume":"196","author":"Sing","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.02.016_bib57","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1128\/IAI.01644-06","article-title":"Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersnia pestis","volume":"75","author":"Pouliot","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.02.016_bib58","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.micinf.2007.04.003","article-title":"The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis","volume":"9","author":"Reithmeier-Rost","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2009.02.016_bib59","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJMcibr070454","article-title":"Tolls and beyond\u2014many roads to vaccine immunity","volume":"356","author":"Pulendran","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2009.02.016_bib60","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20051720","article-title":"Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8 and 9 to stimulate polyvalent immunity","volume":"203","author":"Querec","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.02.016_bib61","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1126\/science.1135299","article-title":"Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling","volume":"314","author":"Gavin","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2009.02.016_bib62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nri2038","article-title":"Cooperation of Toll-like receptor signals in innate immune defence","volume":"7","author":"Trinchieri","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib63","doi-asserted-by":"crossref","first-page":"7984","DOI":"10.1016\/j.vaccine.2007.09.030","article-title":"Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens","volume":"25","author":"Uddowla","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.02.016_bib64","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/eji.200737799","article-title":"Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205\/CD205-positive mouse dendritic cells","volume":"38","author":"Do","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2009.02.016_bib65","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2249.2007.03452.x","article-title":"The fraction 1 and V protein antigens of Yersinia pestis activate dendritic cells to induce primary T cell responses","volume":"149","author":"Kingston","year":"2007","journal-title":"Clin Exp Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09002345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09002345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:54:50Z","timestamp":1684889690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09002345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":65,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0264410X09002345"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.02.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}